An interventional study of Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System in Post Operative Atrial Fibrillation and Atrial Fibrillation, Postoperative, sponsored by AtriCure, Inc.. Recruiting at 37 sites in 2 countries. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by AtriCure, Inc. · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Atrial Fibrillation by AtriCure, Inc. — 2 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · AtriCure, Inc..
Among the 27 studies in Atrial Fibrillation by AtriCure, Inc., this one has the largest planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2025, is one of 16 with no phase, and was the 27th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 27 studies in Atrial Fibrillation by AtriCure, Inc. are open now, in 3 countries. Recruiting first, the newest first:
AtriCure, Inc. · Sites in United States, Austria, Canada
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 3 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 960 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 53 across the 23 interventional studies, 5,020 across the 2 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
AtriCure, Inc. is the lead sponsor of 32 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
2 of the studies in Atrial Fibrillation by AtriCure, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989775AtriCure, Inc.BoxX-NoAF Clinical Trial | 2027-02 |
| NCT05393180AtriCure, Inc.CONVERGE Post-Approval Study (PAS) | 2027-02-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Atrial Fibrillation by AtriCure, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type. Patients with POAF tend to have worse acute and long-term clinical outcomes. BoxX-NoAF is a randomized trial to evaluate if prophylactic ablation and exclusion of the Left Atrial Appendage at the time of other routine cardiac surgery can reduce the incidence of post operative AF and clinical AF during long term follow up in patients who have not yet developed AF but are at risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Index cardiac surgery + Ablation + Left Atrial Appendage Exclusion with AtriClip
Device: Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System
Index cardiac surgery only
Box lesion ablation with the Isolator Synergy EnCompass Clamp System and LAAE using the AtriClip LAA Exclusion System at the time of planned cardiac surgery
Primary Effectiveness Endpoint
The occurrence of clinically relevant post operative AF (POAF)
Time frame: 30 days post index cardiac surgical procedure
Primary Safety Endpoint
The composite of the following events: * All cause Mortality * Reoperation * Deep sternal wound infection * Permanent stroke * Prolonged ventilation * Renal failure * 30-day readmission * Atypical left atrial flutter * Phrenic nerve palsy * Major Bleeding
Time frame: 30 days post index cardiac surgical procedure
Powered Secondary Effectiveness Endpoint
The time to first occurrence of clinical atrial fibrillation from 30 days after index cardiac surgical procedure through 3-years
Time frame: 3 years post index cardiac surgical procedure
Not enrolling at this site — choose another above.
Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.
Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 16 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.